Compare RDWR & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDWR | ALVO |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | Israel | Luxembourg |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2000 | 2021 |
| Metric | RDWR | ALVO |
|---|---|---|
| Price | $29.64 | $5.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $32.50 | $8.00 |
| AVG Volume (30 Days) | 197.9K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.65 | $13.28 |
| Revenue Next Year | $8.62 | $18.63 |
| P/E Ratio | $59.76 | ★ $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.68 | $2.94 |
| 52 Week High | $32.79 | $9.05 |
| Indicator | RDWR | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 70.04 |
| Support Level | $26.61 | $3.10 |
| Resistance Level | $29.66 | $5.85 |
| Average True Range (ATR) | 1.11 | 0.25 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 36.45 | 76.04 |
Radware Ltd is a provider of application security and delivery solutions for multi-cloud environments. Its solutions secure the digital experience by providing infrastructure, application, and network protection and availability services to companies globally. Its solutions are deployed by, among others, enterprises, carriers, and cloud service providers. The company offers solutions in two main categories: Products offers a range of cloud-based security-as-a-service subscriptions, on-premises hardware and software products, and product subscriptions (or a combination of these) to customers; and Services offers managed services, professional services, technical support and training and certification to customers and partners.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.